• eTheRNA
  • Supplying mRNA constructs for the development of innovative therapies

mRNA production

eTheRNA, has built an impressive know-how and expertise in the production of mRNA constructs for research purposes.

From a strategic point of view, eTheRNA wishes to capitalize on the mRNA-production experience it has built over the last years. This strategic decision is further amplified by eTheRNA's strategy to develop a naked mRNA product that can be directly injected (in vivo), in addition to the existing cellular mRNA product (that is based on autologous dendritic cells that are extracted from the human body to be loaded ex vivo with tumor-associated antigens before being reinjected).

To this end, eTheRNA is certifying a brand new mid-size GMP mRNA production facility with sufficient capacity to provide mRNA production services to third parties.